126 related articles for article (PubMed ID: 12162476)
1. Minimal interaction between gatifloxacin and oxycodone.
Grant EM; Nicolau DR; Nightingale C; Quintiliani R
J Clin Pharmacol; 2002 Aug; 42(8):928-32. PubMed ID: 12162476
[TBL] [Abstract][Full Text] [Related]
2. Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
Grant EM; Zhong M; Fitzgerald JF; Nicolau DP; Nightingale C; Quintiliani R
J Clin Pharmacol; 2001 Feb; 41(2):206-9. PubMed ID: 11210403
[TBL] [Abstract][Full Text] [Related]
3. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
4. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients.
Kanji S; McKinnon PS; Barletta JF; Kruse JA; Devlin JW
Crit Care Med; 2003 May; 31(5):1347-52. PubMed ID: 12771601
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.
Lubasch A; Keller I; Borner K; Koeppe P; Lode H
Antimicrob Agents Chemother; 2000 Oct; 44(10):2600-3. PubMed ID: 10991830
[TBL] [Abstract][Full Text] [Related]
7. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
9. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
[TBL] [Abstract][Full Text] [Related]
10. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
[TBL] [Abstract][Full Text] [Related]
11. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.
Gammaitoni AR; Davis MW
J Clin Pharmacol; 2002 Feb; 42(2):192-7. PubMed ID: 11831542
[TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
Teng R; Dogolo LC; Willavize SA; Friedman HL; Vincent J
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():87-92. PubMed ID: 9222076
[TBL] [Abstract][Full Text] [Related]
14. Grapefruit juice enhances the exposure to oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
[TBL] [Abstract][Full Text] [Related]
15. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
[TBL] [Abstract][Full Text] [Related]
16. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
Vincent J; Teng R; Pelletier SM; Willavize SA; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):23S-26S. PubMed ID: 9935253
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oxycodone after subcutaneous administration in a critically ill population compared with a healthy cohort.
Krishnamurthy RB; Upton RN; Fajumi AO; Lai S; Charlton CS; Ousley RM; Martinez AM; McConnell H; O'Connor SN; Ong J; Macintyre PE; Chapman MJ; Ludbrook GL
Anaesth Intensive Care; 2012 Mar; 40(2):269-74. PubMed ID: 22417021
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
Kokki H; Rasanen I; Reinikainen M; Suhonen P; Vanamo K; Ojanperä I
Clin Pharmacokinet; 2004; 43(9):613-22. PubMed ID: 15217304
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole drastically increases exposure to oral oxycodone.
Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.
Benziger DP; Kaiko RF; Miotto JB; Fitzmartin RD; Reder RF; Chasin M
J Pharm Sci; 1996 Apr; 85(4):407-10. PubMed ID: 8901078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
